Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

Summary

Phase II trial to study the effectiveness of gefitinib in treating patients who have recurrent and/or metastatic head and neck cancer. Biological therapies such as gefitinib may interfere with the growth of tumor cells by blocking an enzyme necessary for cell growth.

Timeline

Start

2001-07

Primary completion

2006-03

Completion

—

Drugs

Indications